The American Association for Cancer Research and the American Society of Clinical Oncology urged the FDA to regulate all tobacco products, including e-cigarettes.
The College of American Pathologists published recommendations for active surveillance of patients with prostate cancer.
NCI launched another in a series of targeted treatment trials referred to as the AdjuvantLungCancer EnrichmentMarkerIdentification andSequencingTrial.
A German company that makes devices now under FDA scrutiny for their potential to spread sarcoma threatened legal action against the U.S. surgeon whose wife's cancer cells were disseminated during routine surgery to remove fibroids.
Emmanuel Farber, a pathologist who made contributions to the understanding of chemical carcinogenesis, died Sunday, Aug. 3.
NCI awarded 53 five-year grants for multi-site clinical trials and care delivery research studies through the NCI Community Oncology Research Program. The program will provide $93 million each year.
The Cancer Letter submitted seven questions to Caris Life Sciences regarding their suite of molecular diagnostic tests, following a conversation with Daniel Hayes (See p. 1), a breast cancer expert at the University of Michigan and who served on an Institute of Medicine committee that recently issued a report on omics testing.
Tumor profiling information Caris Life Sciences provides in its reports isn't backed by sufficient evidence to justify some clinical decisions, said Daniel Hayes, a breast cancer expert at the University of Michigan.
Caris: A Big Player in ProfilingAccording to information posted on its website, Caris has profiled the tumors of more than 60,000 cancer patients from 59 countries since 2006; ordered by 6,000 oncologists. The company says it has over 600 employees and operates four laboratories in three metropolitan areas: Dallas, Boston and Phoenix.
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
